title: [Treatment of non-small cell lung cancer in elderly patients].
abstract: Lung cancer is the most common cause of cancer death. With the aging of the population, more than 50% of patients with non-small cell lung cancer (NSCLC) are older than 65 years. Until recently, there was some scepticism regarding treatment of patients in this age group, prevailing the notion that whatever treatment was given, the balance between the benefits and the side effects was unfavourable. The organ failure dependent of age, the comorbidities, the polimedication and the fragility of elderly people, were responsible for this generalized opinion. In the last few years, this nihilistic approach has changed radically. When deciding what treatment strategy should be used in these patients, the biological age (based on performance status: PS and comorbidities) rather than the chronological age should be taken into account, and the modification of standard treatment plans should only be made when there is a valid reason. This applies equally to surgery, chemotherapy, radiotherapy and the new targeted agents, the therapeutic weapons available to treat this disease. Recently published studies, that specifically analysed elderly patients, proved that if treated adequately, elderly patients with a good PS and without major comorbidities have the same survival rates and quality of life as younger patients. The rising number of elderly patients with lung cancer led the authors to do a review of the literature on this topic.
authors.affiliation: Serviço de Pneumologia, Centro Hospitalar de Coimbra.
authors.forename: Filipa
authors.initials: F
authors.lastname: Costa
authors.forename: Fernando
authors.initials: F
authors.lastname: J Barata
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D003663:Decision Trees; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*